Home
>
US Stocks
>
Applied Therapeutics Inc
Applied Therapeutics Inc
APLT

Applied Therapeutics Inc (APLT)

$15.370.59%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$15.08
Today Low/High$15.08 / $15.73
52 Week Low/High$13.04 / $29.8
Market Cap$389M

Company Details

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1/2 clinical trial in June 2019, read out positive top-line biomarker data in adult Galactosemia patients in January 2020 and announced full data from the trial in April 2020. A pediatric Galactosemia study commenced in June 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.
OrganisationApplied Therapeutics Inc
HeadquatersNew York, New York, US
Employees24
IndustryBiotechnology

Discover more

Frequently Asked Questions

What is Applied Therapeutics Inc (APLT) share price today?

Can Indians buy Applied Therapeutics Inc (APLT) shares?

How can I buy Applied Therapeutics Inc (APLT) shares from India?

Can Fractional shares of Applied Therapeutics Inc (APLT) be purchased?

What are the documents required to start investing in Applied Therapeutics Inc (APLT) stocks?

We are a SEBI registered investement advisor